title: [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy].
abstract: Lipodystrophy resp. lipoatrophy and metabolic disorders under antiretroviral therapy are mainly imputed to protease inhibitors. Nucleoside-analogues are suspected to cause lactatea-cidosis as well. The treatment does not pursue standardized concepts. The lipodystrophic alterations which are not endangering the patient but are often cumbersome for him, can be met by PI-saving therapy in a few cases. Against hyperlipidemia cholesterol-synthesis inhibitors are currently debated. Diabetes-therapy follows the conventional concepts. In case of lactate-acidosis antiretroviral therapy must be discontinued temporarily.
authors.affiliation: Med. Poliklinik, Klinikum Innenstadt der Ludwig-Maximilians-Univ. München.
authors.forename: F D
authors.initials: FD
authors.lastname: Goebel
authors.forename: I
authors.initials: I
authors.lastname: Westner
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000139:chemically induced*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D008060:Lipodystrophy / Q000139:chemically induced*
chemical_list: D019380:Anti-HIV Agents